General Information of Drug (ID: DMNZMH6)

Drug Name
3-iodotyrosine Drug Info
Synonyms
2-amino-3-(4-hydroxy-3-iodophenyl)propanoic acid; 3078-39-5; 3-Iodo-DL-tyrosine; C9H10INO3; 3-iodo-l-tyr; AC1Q4PGG; ACMC-209og3; SCHEMBL159411; AC1L1M60; GTPL5117; CTK7I4445; UQTZMGFTRHFAAM-UHFFFAOYSA-N; MolPort-006-167-934; NSC210787; AKOS022187633; S(-)-3-Iodo-4-hydroxy- phenylamine; TRA0009499; MCULE-7084802066; AN-8912; NSC-210787; FCH1320103; SC-11023; KB-32311; AX8285033; Z5788; 2-Amino-3-(3-iodo-4-hydroxyphenyl)propionic acid; 2-Amino-3-(4-hydroxy-3-iodophenyl)propionic acid; 2-amino-3-(4-hydroxy-3-iodo-phenyl)propanoic acid
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
439744
ChEBI ID
CHEBI:27847
CAS Number
CAS 70-78-0
TTD Drug ID
DMNZMH6

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
L-Phenylalanine DMQXI9F Malnutrition 5B50-5B71 Approved [3]
L-tyrosine DM9O8DT Malnutrition 5B50-5B71 Approved [4]
Tetrahydrobiopterin DMINZ4W Malnutrition 5B50-5B71 Approved [5]
Metyrosine DMBYCU0 Pheochromocytoma 5A75 Approved [6]
L1-79 DMLHPVW Autism spectrum disorder 6A02 Phase 2 [7]
ProSavin DMJ42E6 Parkinson disease 8A00.0 Phase 1/2 [8]
OXB-102 DMXF9DM Parkinson disease 8A00.0 Phase 1/2 [9]
7,8-dihydrobiopterin DMQU4XM Discovery agent N.A. Investigative [10]
alpha-propyldopacetamide DMQKMX3 Discovery agent N.A. Investigative [2]
Meta-Tyrosine DM0748C Discovery agent N.A. Investigative [10]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Tyrosine 3-monooxygenase (TH) TTUHP71 TY3H_HUMAN Inhibitor [2]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5117).
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1243).
3 Selectivity and affinity determinants for ligand binding to the aromatic amino acid hydroxylases. Curr Med Chem. 2007;14(4):455-67.
4 Effect of metals and phenylalanine on the activity of human tryptophan hydroxylase-2: comparison with that on tyrosine hydroxylase activity. Neurosci Lett. 2006 Jul 3;401(3):261-5.
5 Biochemistry of postmortem brains in Parkinson's disease: historical overview and future prospects. J Neural Transm Suppl. 2007;(72):113-20.
6 Dopamine beta-hydroxylase deficiency. A genetic disorder of cardiovascular regulation. Hypertension. 1991 Jul;18(1):1-8.
7 Effect of L1-79 on Core Symptoms of Autism Spectrum Disorder: A Case Series. Clin Ther. 2019 Oct;41(10):1972-1981.
8 Clinical pipeline report, company report or official report of Oxford BioMedica.
9 Clinical pipeline report, company report or official report of Oxford BioMedica.
10 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.